2,423 Shares in The Clorox Company (NYSE:CLX) Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. purchased a new stake in shares of The Clorox Company (NYSE:CLX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,423 shares of the company’s stock, valued at approximately $395,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CLX. Fiduciary Group LLC boosted its position in Clorox by 0.4% in the second quarter. Fiduciary Group LLC now owns 19,050 shares of the company’s stock valued at $2,600,000 after buying an additional 72 shares during the last quarter. GHP Investment Advisors Inc. increased its stake in shares of Clorox by 2.0% in the second quarter. GHP Investment Advisors Inc. now owns 3,634 shares of the company’s stock worth $496,000 after acquiring an additional 72 shares during the period. SPC Financial Inc. raised its holdings in shares of Clorox by 2.2% during the second quarter. SPC Financial Inc. now owns 3,485 shares of the company’s stock worth $476,000 after purchasing an additional 75 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Clorox by 17.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 510 shares of the company’s stock valued at $83,000 after purchasing an additional 75 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in Clorox by 5.1% in the second quarter. Mesirow Financial Investment Management Inc. now owns 1,702 shares of the company’s stock valued at $233,000 after purchasing an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Trading Down 0.6 %

CLX stock opened at $156.82 on Wednesday. The Clorox Company has a 12-month low of $114.68 and a 12-month high of $169.09. The business’s 50-day moving average is $161.02 and its 200 day moving average is $145.82. The company has a current ratio of 1.03, a quick ratio of 0.63 and a debt-to-equity ratio of 5.04. The stock has a market cap of $19.48 billion, a price-to-earnings ratio of 81.25, a PEG ratio of 3.19 and a beta of 0.41.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.28. Clorox had a return on equity of 281.12% and a net margin of 3.95%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.97 billion. On average, sell-side analysts anticipate that The Clorox Company will post 6.64 EPS for the current fiscal year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 7th. Stockholders of record on Wednesday, October 23rd will be paid a $1.22 dividend. This represents a $4.88 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Wednesday, October 23rd. Clorox’s dividend payout ratio is currently 252.85%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CLX. Jefferies Financial Group upgraded Clorox from a “hold” rating to a “buy” rating and lifted their price objective for the company from $174.00 to $187.00 in a research note on Tuesday, October 1st. Wells Fargo & Company decreased their price target on Clorox from $135.00 to $130.00 and set an “underweight” rating for the company in a report on Wednesday, July 10th. JPMorgan Chase & Co. raised their price objective on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a research note on Friday, October 11th. Citigroup boosted their target price on shares of Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. Finally, Barclays raised their price target on shares of Clorox from $130.00 to $137.00 and gave the company an “underweight” rating in a research report on Friday, October 11th. Six analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $150.14.

Insider Buying and Selling

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the transaction, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at $2,229,719.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.51% of the stock is currently owned by company insiders.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.